Phase I trial of 131-I mIBG, Nivolumab and dinutuximab beta in children with relapsed and refractory neuroblastoma | University of 天发娱乐棋牌_天发娱乐APP-官网|下载_天发娱乐棋牌_天发娱乐APP-官网|下载
$500,000 funding from Solving Kids Cancer, $680,000 funding from BMS and $100,000 from EUSA Pharma. Juliet Gray is international lead / chief investigator